Cannabinoid and Vasodilator Compositions for Sexual Dysfunction

The patent combines two distinct types of compounds: (1) compounds that enhance blood flow to the genital region (e.g., PDE5 inhibitors like sildenafil) and (2) cannabinoid compounds (e.g., THC, CBD) that address psychological and emotional aspects. This merging of physiological and psychological agents creates a comprehensive treatment that simultaneously improves performance ability and enhances pleasure/sensitivity, resolving the contradiction between reliable performance and sensory enhancement.

The patent creates a multi-functional pharmaceutical preparation that simultaneously addresses multiple aspects of sexual dysfunction: physiological (blood flow enhancement), psychological (anxiety reduction through cannabinoids), and emotional (pleasure enhancement). This universal approach allows a single preparation to treat diverse underlying causes including stress, anxiety, depression, and physiological impairment, making the treatment adaptable to various patient conditions rather than requiring separate treatments for each aspect.

The patent employs a composite pharmaceutical formulation combining PDE5 inhibitors (which restore erectile function through vasodilation) with cannabinoid compounds (which enhance sensitivity and pleasure through central nervous system effects). This composite material approach allows the preparation to deliver both performance restoration and sensory enhancement simultaneously, overcoming the limitation of conventional monotherapy that only addresses performance without recovering sensitivity and enjoyment.